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Conclusion: Injection of pASC in renal graft artery at reperfusion of the grafts
in a porcine model mimicking deceased after cardiac arrest donor conditions
improves graft function recovery and limits tubular damages. These therapeutic
potentials will be confirmed by further studies at the end of the follow-up at
3 months.
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Experimental models of renal ischemia/reperfusion (I/R) have suggested
protective effects of mesenchymal stromal cells (MSC) therapy. Still, param-
eters of MSC injection, including volume, route and timing of cell administration,
remain largely debated. Particularly, MSC infusion in mouse has been shown to
be beneficial “a priori” but deleterious “a posteriori” of renal I/R injury. In order to
further investigate the influence of the timing of MSC administration, we used
10-week-old Lewis rats categorized in 4 groups. Groups 1 (MSC D-7, n = 10)
and 2 (MSC D + 1, n = 7) received caudal i.v. injection of MSC (1.5 9 106 in
1 ml of saline) 7 days before or 1 day after renal I/R, respectively. Control
groups 3 (saline D-7, n = 6) and 4 (saline D + 1, n = 6) received equal volume
of saline at similar time points. Left renal ischemia (by clamping of the renal
pedicle) lasted 45 min. Right nephrectomy was simultaneously performed.
Blood sample was collected from inferior vena cava at 48 h post reperfusion.
MSC phenotype was confirmed by FACS analysis. In groups 1 and 3, serum
creatinine (SCr) reached 1.4 ! 0.7 versus 2.4 ! 0.8 mg/dl, respectively
(p < 0.05). In groups 2 and 4, SCr was 4.9 ! 0.7 versus 3.3 ! 0.9 mg/dl,
respectively (p < 0.001). Furthermore, SCr levels were statistically worse when
MSC were administered after renal I/R in comparison to a priori infusion
(p < 0.0001). In conclusion, MSC administration 7 days prior to renal I/R
attenuates kidney injury in comparison to (i) saline infusion or (ii) MSC infusion
1 day after renal I/R. Conversely, on the basis of SCr levels, MSC therapy
performed after renal I/R worsens kidney injury in rats.
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Background: Animal models of CKD show that a selected population of
bioactive renal cells (SRC) can be delivered through parenchymal injection
resulting in a decrease in disease progression. It has been shown to 1) reduce
chronic infiltration by monocytes/macrophages and T-lymphocytes and atten-
uate the NFjB response 2) promote tubular cell expansion. We used a
laparoscopic technique to perform a study with Neo-Kidney Augment (NKA).
Methods: Six type-2 diabetic (108 ! 11 kg) patients (64 ! 6 years) with
CKD 3–4 were selected. After evaluation of iohexol clearance, MRI, renal
scintigraphy and albumine-creatinine ratio (ACR) patients underwent a regular
renal biopsy. Two cores were shipped to the Tengion (Winston Salem, NC,
USA) for tissue separation, cell isolation and product preparation. NKA was
shipped back to Karolinska (range 59–87 days after biopsy) for intracortical
injection using a laparoscopic hand-assisted retroperitoneal technique (HARS).
Results: No complications occurred at biopsies. All resulted in material being
used to obtain NKA. Implantation of 8 ml NKA into the left kidney was
uneventful. No bleeding occurred at the site. A postoperative complication was
observed in one patient (ileocecal volvolus, leading to a right-sided hemicolec-
tomy). Infectious complications (hospitalizations) were observed in three
patients in the first three months. Antihypertensive medication has been
reduced 3/6 patients during the first 6 m following implant. S-creatinine has
remained stable at 6 and 12 months after autologous renal cell implantation in
four out of the five first patients. In patient 03 the rise in s-creatinine has been
related to postrenal obstruction.
Conclusion: NKA was safely implanted in six T2DM patients. In this
population complications after the implantations were related to the surgical
procedure. Longer follow-up and more patients are needed to reveal if this
technique can arrest porogression of CKD and delay the start of renal
replacenent therapy.
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